Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC
<p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Consi...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-10-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/546 |
id |
doaj-39fc521f528d4b60821d871f7bf528be |
---|---|
record_format |
Article |
spelling |
doaj-39fc521f528d4b60821d871f7bf528be2020-11-24T20:51:30ZengBMCBMC Cancer1471-24072010-10-0110154610.1186/1471-2407-10-546Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMICWindemuth-Kieselbach ChristineNikoghosyan AnnaJensen Alexandra DDebus JürgenMünter Marc W<p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.</p> <p>Methods/design</p> <p>The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).</p> <p>Discussion</p> <p>The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all salivary gland malignancies.</p> <p>Trial Registration</p> <p>Clinical trial identifier NCT 01154270</p> http://www.biomedcentral.com/1471-2407/10/546 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Windemuth-Kieselbach Christine Nikoghosyan Anna Jensen Alexandra D Debus Jürgen Münter Marc W |
spellingShingle |
Windemuth-Kieselbach Christine Nikoghosyan Anna Jensen Alexandra D Debus Jürgen Münter Marc W Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC BMC Cancer |
author_facet |
Windemuth-Kieselbach Christine Nikoghosyan Anna Jensen Alexandra D Debus Jürgen Münter Marc W |
author_sort |
Windemuth-Kieselbach Christine |
title |
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC |
title_short |
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC |
title_full |
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC |
title_fullStr |
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC |
title_full_unstemmed |
Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC |
title_sort |
combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (imrt) and carbon ions: cosmic |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2010-10-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Local control in malignant salivary gland tumours is dose dependent. High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy. Considering high doses are needed to achieve local control, all malignant salivary gland tumours probably profit from the use of particle therapy, which in case of carbon ion treatment, has been shown to be accompanied by only mild side-effects.</p> <p>Methods/design</p> <p>The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).</p> <p>Discussion</p> <p>The primary objective of COSMIC is to evaluate toxicity and feasibility of the proposed treatment in all salivary gland malignancies.</p> <p>Trial Registration</p> <p>Clinical trial identifier NCT 01154270</p> |
url |
http://www.biomedcentral.com/1471-2407/10/546 |
work_keys_str_mv |
AT windemuthkieselbachchristine combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic AT nikoghosyananna combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic AT jensenalexandrad combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic AT debusjurgen combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic AT muntermarcw combinedtreatmentofmalignantsalivaryglandtumourswithintensitymodulatedradiationtherapyimrtandcarbonionscosmic |
_version_ |
1716802084870815744 |